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The direct binding of bacteria to platelets may be an important virulence mechanism in the pathogenesis of
infective endocarditis. We have previously described Staphylococcus aureus strain PS12, a Tn551-derived
mutant of strain ISP479, with reduced ability to bind human platelets in vitro. When tested in an animal model
of endocarditis, the PS12 strain was less virulent than its parental strain, as measured by bacterial densities
in endocardial vegetations and incidence of systemic embolization. We have now characterized the gene
disrupted in PS12 and its function in platelet binding. DNA sequencing, Southern blotting, and PCR analysis
indicate that PS12 contained two Tn551 insertions within the clumping factor A (ClfA) locus (clfA). The first
copy was upstream from the clfA start codon and appeared to have no effect on ClfA production. The second
insertion was within the region encoding the serine aspartate repeat of ClfA and resulted in the production of
a truncated ClfA protein that was secreted from the cell. A purified, recombinant form of the ClfA A region,
encompassing amino acids 40 through 559, significantly reduced the binding of ISP479C to human platelets by
44% (P ⴝ 0.0001). Immunoprecipitation of recombinant ClfA that had been incubated with solubilized platelet
membranes coprecipitated a 118-kDa platelet membrane protein. This protein does not appear to be glycoprotein IIb. These results indicate that platelet binding by S. aureus is mediated in part by the direct binding
of ClfA to a novel 118-kDa platelet membrane receptor.
The binding of bacteria to platelets is thought to be a major
virulence determinant in the pathogenesis of infective endocarditis (28). Platelet binding may be an important mechanism
for initiating endocardial infection, since platelets attached to
damaged valve surface may serve as binding foci for organisms
circulating in the blood (10, 30, 36). In addition, the adhesion
of bacteria to platelets may be important for the subsequent
development of mature vegetations (7). Bacteria on the valve
surface may recruit circulating platelets to that site, resulting in
the further deposition of platelets. These events, in conjunction with bacterial proliferation, eventually lead to the formation of macroscopic endocardial vegetations.
Previous studies have shown that Staphylococcus aureus can
bind to platelets in vitro (1, 29). This binding is likely to be
mediated in part by soluble bridging molecules that link the
organism to the platelet surface. S. aureus binds a number of
soluble host proteins that may serve as bridging molecules,
including fibrinogen, fibronectin, thrombospondin, and von
Willebrand factor (3, 15, 16, 18). Since these proteins can also
bind activated platelets, it is likely that these molecules could
contribute to staphylococcal binding to human platelets in vivo.
S. aureus has also been shown to bind human platelets directly. The mechanisms for direct binding have not been characterized extensively, but it is likely that such binding is multifactorial. Our previous studies have indicated that binding
may be mediated in part by surface carbohydrates (including
the staphylococcal capsule) and one or more surface proteins

(36). Recent studies have also shown that staphylococcal protein A can bind platelet gC1qR, a receptor that is expressed on
the surface of activated platelets (24). Thus, this latter interaction may be an additional mechanism for the direct attachment of staphylococci to platelets on the endocardial surface.
Although the binding of S. aureus to platelets may occur by
multiple processes, the impact of the above interactions on the
pathogenesis of endocarditis is largely unknown. Our previous
studies have focused on the role of direct binding of S. aureus
to unactivated platelets in the pathogenesis of bacterial endocarditis. These studies have described a mutant of S. aureus
strain ISP479, derived by transposon mutagenesis, with both
decreased direct binding to platelets in vitro and reduced virulence in an animal model of endocarditis (29). Rabbits infected with mutant strain PS12 had lower densities of S. aureus
within vegetations and lower rates of systemic embolization
than those of rabbits infected with the parental strain. These
results demonstrated that the direct binding of S. aureus to
platelets may be an important mechanism for the pathogenesis
of endocarditis.
To better define the molecular basis of direct platelet binding by S. aureus, we have now characterized extensively the
mutation within strain PS12. Our results indicate that staphylococcal clumping factor A (ClfA) (21), recognized initially for
its role in fibrinogen binding, also mediates direct binding to
human platelets. As discussed below, ClfA appears to bind a
novel 118-kDa protein on the platelet membrane.

* Corresponding author. Division of Infectious Diseases, VA Medical Center (111W), 4150 Clement St., San Francisco, CA 94121.
Phone: (415) 221-4810, ext. 2550. Fax: (415) 750-0502. E-mail: sullam
@itsa.ucsf.edu.

MATERIALS AND METHODS
Bacterial strains, plasmids, and primers. The bacterial strains, plasmids, and
primers used in this study are listed in Table 1.
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TABLE 1. Bacterial strains, plasmids, and primers used in this study
Bacterial strain,
plasmid, or primer

Genotype or description

Reference
or source

S. aureus strains
ISP479C
PS12
Newman
DU5852

Derivative of 8325-4 cured of the Tn551 delivery plasmid pI258
Low-platelet binding mutant of ISP479
Wild-type strain
Newman clfA::Tn917

26
29
8
21

E. coli strains
DH5␣
BL21(DE3)
MC1061

F⫺ 80dlacZ⌬M15 ⌬(lacZYA-argF)U169 endA1 recA1 hsdR17(rK⫺ mK⫹) deoR thi-1 supE44 ⫺ gyrA96 relA1
F⫺ ompT hsdSB(rB⫺ mB⫺) gal dcm (DE3)
F⫺ araD139 ⌬(ara-leu)7696 galE15 galK16 ⌬(lac)X74 rpsL(Strr)hsdR2(rK⫺ mK⫺) mcrA mcrB1

35
27
33

E. coli cloning vector
T7 expression vector
Shuttle vector containing Tn917
pBluescriptSK(⫺) containing a Tn551-PS12 XhoI fragment cloned into the XhoI site of the vector
Variant of pRS401 from which a 3.5-kb PstI fragment had been deleted
pET28A containing the clfA sequence corresponding to amino acids 40-559 as an in-frame N-terminal fusion with the His6 and T7 tags

Stratagene
Novagen

5⬘-CGCGGATCCAGTGAAAATAGTGTTACGCAATCT-3⬘; forward primer for cloning ClfA40-559a
5⬘-CGCAAGCTTCTCTGGAATTGGTTCAATTTC-3⬘; reverse primer for cloning ClfA40-559
5⬘-TCGATACAAATTTCTCGTGCGCTCGGACCCC-3⬘; Tn551 left and right end primer
5⬘-TTTTGCTGCTTCAGTGTCAGA-3⬘; forward primer for ORF downstream of clfA
5⬘-GGCTGAAGATGAGGCTTTGA-3⬘; reverse primer for ORF downstream of clfA

25
25

Plasmids
pBluescript SK(⫺)
pET28A
pLTV1
pRS401
pRS402
pRS404
Primers
DOCF1
DOCR1
TNEND
DSF
DSR
a

ClfA40-559, ClfA with amino acids 40 to 559.

Media and antibiotics. Brain heart infusion (BHI) and Luria-Bertani (LB)
broth and agar were used as culture media for S. aureus and Escherichia coli, respectively. Erythromycin was used at a concentration of 15 g/ml for selection of
S. aureus and at 500 g/ml for E. coli when these strains contained the erm gene.
Kanamycin and ampicillin were used at a concentration of 50 g/ml where
appropriate.
DNA sequencing. Chromosomal DNA was prepared from lysostaphin-treated
PS12 strain as described previously (2), digested with XhoI, and ligated into
pBluescript SK(⫺) that had been digested with the same enzyme. The Tn551PS12 junction was sequenced using an ABI automated system (Applied Biosciences). Initial sequencing reactions were performed using the T7 and T3
primers. Subsequent reactions were done using primers based on derived staphylococcal sequences.
Southern blotting. S. aureus chromosomal DNA was digested with selected
restriction enzymes and transferred to Biodyne A membrane (Pall Corporation),
using the Turboblotter Transfer System (Schleicher & Schuell Inc.). A 3.9-kb
gel-purified fragment of Tn917, which has 98% homology to Tn551 (determined
by sequence alignment), was labeled with digoxigenin (DIG/Genius System;
Roche Diagnostics) for use as a probe. Hybridization was performed in a highstringency buffer at 42°C, and then washing and imaging by chemiluminescence
were done, according to the manufacturer’s instructions.
Protein extraction. Cell wall proteins were isolated from S. aureus by the
method of Hartford et al. (12). In brief, cultures of bacteria grown overnight
were washed in phosphate-buffered saline (PBS) and incubated for 30 min at
37°C in protoplasting buffer (50 mM Tris-HCl, 30% [wt/vol] raffinose, 145 mM
NaCl [pH 7.5]) containing complete protease inhibitor (Roche Diagnostics),
DNase I (80 g/ml; Sigma), and lysostaphin (20 g/ml; Sigma). The protoplasts
were removed by centrifugation (12,000 ⫻ g for 10 min), and the protein concentration in the supernatant was determined using the BCA Protein Assay
Reagent kit (Pierce). To isolate proteins from culture supernatants, 900 l of
spent media was precipitated with trichloroacetic acid, washed twice with 1 ml of
acetone, and suspended in 20 l of PBS.
SDS-PAGE and Western immunoblotting. Proteins were prepared for electrophoresis in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) sample buffer and separated through 7.5% polyacrylamide gels (19). The
proteins were then transferred electrophoretically to BioTrace NT membranes
(Pall Corporation) by semidry transfer in Towbin buffer (31). The membranes
were treated with a casein-based solution (blocking reagent; Roche Diagnostics)
and then incubated overnight at 4°C with polyclonal rabbit anti-ClfA region A
antiserum (1:1,000; kindly provided by T. J. Foster, Trinity College, Dublin,
Ireland). Goat anti-rabbit immunoglobulin G conjugated to horseradish peroxidase was used to detect ClfA by chemiluminescence (Roche Diagnostics).

Northern (RNA) blot hybridization. S. aureus RNA was prepared and blotted
with the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions.
Cultures were lysed in 100 l of a solution containing 10 mM Tris-HCl and 1 mM
EDTA (pH 8.0) supplemented with lysozyme (3 mg/ml; Sigma), lysostaphin (20
g/ml), and Anti-RNase (15 U; Ambion). Samples were separated via electrophoresis through a 1% agarose–0.66% formaldehyde gel in MOPS [3-(N-morpholino)propanesulfonic acid] running buffer. The RNA was transferred to positively charged nylon membranes (Roche Diagnostics) as described above.
Hybridization was performed under high-stringency conditions, with PCR-generated, digoxigenin-labeled DNA probes, followed by washing and imaging by
chemiluminescence, according to the manufacturer’s instructions.
Assay for binding of staphylococci to soluble fibrinogen. The ability of S.
aureus to clump in the presence of soluble human fibrinogen was assessed by a
turbidometric assay. Cultures of S. aureus were grown in BHI broth for 18 h at
37°C, washed as described above, and suspended in HEPES buffer (20 mM
HEPES, 140 mM NaCl, 1 mM EDTA [pH 7.5]) to a final concentration of
approximately 108 CFU/ml. Four hundred and fifty microliters of the diluted
culture were added to siliconized glass tubes, placed in an aggregometer (Chronolog, Havertown, Pa.) and stirred continuously at 37°C. After a transmittance
baseline was established, human fibrinogen (final concentration of 50 g/ml; Sigma) was added to the tube, and the mixture was monitored for changes in light
transmission. Clumping was detected as an increase in light transmission, with suspensions of bacteria alone and PBS serving as standards for minimal and maximal light transmission, respectively. All assays were performed at least three times.
Assay for binding of staphylococci to immobilized fibrinogen. The binding of
S. aureus to immobilized fibrinogen was quantified by an agar overlay assay. S.
aureus was prepared as described above, washed twice in HEPES buffer, sonicated for 15 s to disperse clumps, and adjusted to a final concentration of
approximately 103 CFU/ml. One milliliter of diluted culture was added to 25mm-diameter culture wells that had been coated overnight with 1 ml of fibrinogen in PBS (50 g/ml). The plates were incubated at 4°C for 1 h on a rotary
shaker, followed by washing with agitation (three times for 5 min each time) to
remove nonadherent bacteria. Two milliliters of BHI medium containing 0.5%
agar were then added to the wells and allowed to solidify. After incubation of the
plates overnight at 37°C, the number of colonies in each well was determined,
and binding was expressed as a percentage of inoculum. All assays were performed at least six times.
Expression and purification of recombinant protein ClfA with amino acids 40
through 559 (rClfA). A PCR-amplified fragment of the clfA gene (corresponding
to the A region of the protein) was cloned into pET28A (Novagen). Recombinant proteins produced from this construct contain an N-terminal extension of
six histidine residues. After transforming E. coli BL21(DE3) with the resultant
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plasmid, the protein was expressed and purified, using the His-Bind Purification
kit (Novagen), according to the manufacturer’s instructions. Subsequent to elution, the recombinant protein was dialyzed against PBS containing 10% glycerol
and then stored at ⫺70°C.
Assay for staphylococcal binding to platelet monolayers. Staphylococcal binding to human platelet monolayers was assayed as described previously (29). In
brief, 18-h-old cultures of S. aureus were washed twice in HEPES buffer, sonicated for 15 s to disperse clumps, and adjusted to a final concentration of A600
of 0.15 (approximately 107 CFU/ml). Fifty microliters of each suspension was
added to individual 6-mm-diameter microtiter wells that had been previously
coated with fixed, inactive human platelet monolayers and blocked with the
above casein-based solution to reduce nonspecific binding. The plates were
incubated at 4°C for 1 h, and the wells were washed three times for 5 min with
HEPES buffer to remove nonadherent bacteria. The wells were then treated with
50 l of trypsin (1 mg/ml) for 30 min at room temperature to release the bound
bacteria from the platelets. The number of bound bacteria was determined by
plating serial dilutions of the recovered organisms onto blood agar plates, and
binding was expressed as a percentage of inoculum.
To assess the ability of ClfA to block the binding of S. aureus to human
platelets, monolayers were treated with increasing concentrations of purified
rClfA (0 to 50 g/ml; 60 min, 4°C). Aliquots of ISP479C were prepared as
described above and added to the platelet monolayers. As a control, parallel
studies were done using platelets that had not been exposed to rClfA. Platelet
binding under both conditions was then assessed as described above. Six binding
values were recorded for each strain per assay, with each strain tested on multiple occasions.
Isolation of platelet membranes. Platelet membranes were prepared by glycerol lysis and gradient centrifugation (11). In brief, 1 U of human platelet
concentrate (obtained from the Blood Centers of the Pacific, San Francisco,
Calif.) was centrifuged (900 ⫻ g, 22°C, 10 min). The resultant platelet pellets
were washed in buffer A (10 mM sucrose, 130 mM NaCl, 4 mM monobasic
sodium phosphate, 7.5 mM dibasic sodium phosphate, 5 mM sodium citrate
dihydrate [pH 6.7]). The platelets were then suspended in 10 ml of buffer B (85
mM Tris-Cl, 965 mM NaCl, 857 mM glucose, 10 mM EDTA, 100 mM EGTA
[pH 7.4]), layered onto 30 ml of a 0 to 40% linear gradient made in buffer C (1:10
dilution of buffer B), and centrifuged first at 1,500 ⫻ g for 30 min and then at
5,900 ⫻ g for 10 min. The glycerol was removed, and the pellet was lysed in 4 to
5 volumes of buffer C containing complete protease inhibitor. The sample was
centrifuged (5,900 ⫻ g, 10 min) to remove unlysed platelets, and the supernatant
was applied to a sucrose step gradient (10 ml of 33% sucrose on 5 ml of 66%
sucrose in buffer C). After centrifugation in an SW28 rotor (90 min, 63,000 ⫻ g,
4°C), the membranes were removed, dialyzed against PBS containing 10% glycerol, and stored at ⫺70°C.
Coimmunoprecipitation. Platelet membranes (25 g of total protein) were
labeled with sulfosuccinimidyl-6-(biotinamido)hexanoate (Pierce) according to
the manufacturer’s instructions and then solubilized in binding buffer (PBS, 10%
glycerol, 1.5% Triton X-100). The solubilized membrane proteins were incubated with 10 g of rClfA in binding buffer (4°C, 60 min), followed by the
addition of 30 l of protein A-Sepharose that had been preincubated with 5 g
of anti-His monoclonal antibody (Amersham Pharmacia). This antibody specifically recognizes the histidine fusion tag on recombinant proteins. As controls for
nonspecific binding, solubilized platelet membranes were also incubated separately with washed protein A-Sepharose alone or protein A-Sepharose coupled
with anti-His. After further incubation (4°C, 60 min), the protein complexes were
washed (three times with 1 ml of PBS–100 mM NaCl–0.1% Triton X-100, once
with 1 ml of PBS–0.1% SDS, and once with 1 ml of PBS) and boiled in SDSPAGE sample buffer to release the bound platelet membrane proteins. Following electrophoresis and transfer to Biotrace NT membranes, the recovered proteins were analyzed by Western blotting using a monoclonal antibody specific for
glycoprotein IIb (GPIIb) (SZ22; Immunotech) or by probing with streptavidin
conjugated to horseradish peroxidase.
Statistical methods. Differences in platelet and fibrinogen binding were compared using the Student t test. P values of less than 0.05 were considered
significant.

RESULTS
Identification of the gene interrupted in S. aureus PS12. To
determine the site of the Tn551 insertion within the PS12
chromosome, XhoI fragments of the PS12 genome were cloned
into pBluescript SK(⫺). E. coli MC1061 was transformed with
the ligation products by electroporation, followed by plating on

FIG. 1. Schematic representation of the S. aureus clumping factor
gene (clfA) including relevant subdomains. The relevant subdomains
are indicated as follows: 1, Signal sequence; 2, fibrinogen binding A
region; 3, SD repeat; 4, wall anchor (LPXTG) and membrane-spanning domain. The positions and orientations of the Tn551 insertions
are indicated. Abbreviations: H, HindIII; P, PstI; X, XhoI.

LB agar supplemented with 500 g of erythromycin per ml to
select for clones containing plasmids with the erm gene of
Tn551 and flanking PS12 DNA. Electrophoretic analysis of
plasmid DNA from 10 randomly selected, erythromycin-resistant clones indicated that all 10 constructs contained inserts of
6.2 kb. One such plasmid (pRS401) was chosen for further
characterization. DNA sequencing from the T7 and T3 primer
sites on this plasmid indicated that two copies of the erm gene
were present, with one located adjacent to each of the primer
sites. Additional sequencing of pRS401 was performed using a
primer (TNEND) that specifically hybridized with both ends of
Tn551 (which are identical). Amplification of the plasmid insert in this manner produced two fluorescent signals at each
nucleotide position, further suggesting that more than one
copy of Tn551 was present. To circumvent this problem, we
removed the 3.5-kb PstI fragment adjacent to the T3 primer
site of pRS401, thereby producing the construct pRS402. Sequencing of pRS402 from the T3 site indicated that the chromosomal fragment cloned into the construct was a portion of
the clumping factor gene clfA, which encodes a major fibrinogen binding protein of S. aureus (21). Sequencing of the entire
insert in pRS401 was then completed using primers derived
from the clfA sequence. The resultant sequence data confirmed that two copies of Tn551 had inserted in the PS12
chromosome. One copy is located upstream of the clfA start
codon, and a second copy is inserted in a region encoding
serine aspartate repeats (SD repeat) of the protein (Fig. 1).
Confirmation of transposon copy number. To further establish that two copies of the transposon had inserted in the S.
aureus PS12 chromosome, Southern blotting was performed,
using a probe specific for Tn551. This 3.9-kb probe encompasses 75% of the transposon sequence and overlaps both of
the HindIII sites within Tn551. As we described previously
(29), the probe appeared to hybridize with three bands in the
HindIII digest of PS12 chromosomal DNA, suggesting that a
single copy of the transposon was present. However, analysis of
the DNA sequence flanking clfA indicated that HindIII digestion of this region could produce fragments of similar size. We
were concerned, therefore, that Southern blotting of such digests could underestimate the number of Tn551 insertions
within this region. For this reason, we examined a PS12 chromosomal DNA that had been treated with a different endonuclease. When examined by Southern blotting, the same probe
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FIG. 4. Localization of ClfA from S. aureus ISP479C and PS12.
Western blot analysis of cell wall extracts and spent culture media
precipitates from ISP479C and PS12. An equivalent volume of uninoculated media (BHI) was included as a control. The proteins were
probed with antiserum raised against the A region of ClfA. Compared
with the parental strain, ClfA was nearly undetectable in the cell wall
extracts of PS12. Note the truncated form of the protein detected in
the culture supernatants of PS12. TCA, trichloroacetic acid.

FIG. 2. Southern blots of S. aureus PS12 chromosomal DNA digested with HindIII (lane 1) or PstI (lane 2). Chromosomal digests
were hybridized with a digoxigenin-labeled, 3.9-kb fragment of Tn917
and imaged by chemiluminescence.

hybridized with two bands in a PstI digest of the PS12 DNA
(Fig. 2). Since Tn551 contains no PstI site, these latter results
indicate that two copies of the transposon were inserted within
the chromosome of PS12, thus confirming the DNA sequence
data.
Sequencing also indicated that the two copies of Tn551 were
inserted in opposite orientations within the S. aureus PS12
chromosome and separated by 2.6 kb. To confirm that two
copies of Tn551 were present, a single primer (TNEND) corresponding to the end of the transposon was used to amplify
PS12 chromosomal DNA by PCR. Since one primer was used
in the reaction, a product could be obtained only if two copies
of the transposon were present. As predicted, amplification
produced a single fragment of 2.6 kb (Fig. 3), confirming that

FIG. 3. PCR amplification of S. aureus PS12 chromosomal DNA. A
single primer that recognizes the end of Tn551 was used to amplify
chromosomal DNA from PS12. Lane 1, size standards; lane 2, single
2.6-kb product generated from the reaction.

two copies of the transposon were inserted in opposite orientations within the PS12 genome.
Characterization of the effect of transposon insertion on
protein expression. To assess the effects of the two transposon
insertions on ClfA production, we examined the surface expression and extracellular secretion of ClfA by the parental
and mutant strains. Western blot analysis of cell wall extracts
probed with anti-ClfA region A antibodies indicated that
clumping factor was present in the cell wall of S. aureus
ISP479C. As noted previously with ClfA recovered from lysostaphin extracts (20), the protein migrated as two distinct
bands with molecular masses of approximately 130 and 185
kDa. In contrast, little or no clumping factor was associated
with the cell wall of PS12. Probing spent culture media of
ISP479C in the same manner demonstrated that ClfA was
present, though with an apparent increase in molecular mass.
Western blotting of the culture supernatant from the mutant
revealed that a truncated form of the protein was produced
and released into the medium (Fig. 4). These results indicate
that ClfA is still synthesized by PS12 but the protein is smaller
and not retained in the wall of the organism. The production of
truncated ClfA further indicates that the downstream copy of
Tn551, which is inserted with the coding region, is responsible
for the reduced platelet binding observed with strain PS12.
Disruption of clfA is not transcriptionally polar. To confirm
that the reduced platelet binding associated with disruption of
clfA was not due to polar effects, we examined the transcription
of the open reading frame (ORF) immediately downstream of
clfA. This ORF was identified from the staphylococcal genome
database at the University of Oklahoma, and based on that
sequence, a 543-bp DNA probe specific for a portion of the
coding sequence of the downstream ORF was generated by
PCR. When RNA prepared from ISP479C was examined by
Northern blotting, no hybridization with the probe was observed. The inability to detect transcripts by Northern blotting
of RNA extracted from ISP479C was not wholly unexpected.
Previous studies examining the expression of genes encoded by
ISP479 had encountered similar difficulties, necessitating the
use of another strain (34). For this reason, we then assessed the
expression of the downstream ORF in S. aureus strain Newman. An isogenic variant of Newman (strain DU5852) in which
clfA was disrupted by Tn917 was also assessed. When RNA
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FIG. 5. Northern blot analysis of total RNA isolated from S. aureus
strains Newman (lane 1) and DU5852 (lane 2) grown to mid-exponential phase and hybridized with a digoxigenin-labeled probe generated
from the ORF immediately downstream of clfA. Note the band at
approximately 1.8 kb (arrow) for both samples, representing the transcript downstream of clfA. 23S and 16S rRNA can also be seen at
approximately 2.8 and 1.5 kb, respectively.

from these strains was hybridized with the above 543-bp probe,
transcripts of 1.6 kb were readily visible in both the Newman
and DU5852 strains (Fig. 5). Thus, the transposon insertion
within clfA does not alter downstream gene expression, indicating that the reduced platelet binding seen in PS12 is likely
due to disruption of clfA and not a result of polar effects.
Binding of S. aureus to fibrinogen. It was surprising to find
that clfA was disrupted in PS12, since we had observed previously that the binding of soluble, radiolabeled fibrinogen by
strains PS12 and ISP479C were comparable (29). To assess the
fibrinogen binding properties of these strains in greater detail,
we compared their ability to clump in the presence of soluble
fibrinogen, as measured by a turbidimetric assay. Strain Newman, in which ClfA was first identified, was used as a positive
control. Addition of fibrinogen to Newman in suspension produced rapid clumping, with maximal (100%) light transmission
occurring within 10 min (Fig. 6). In contrast, addition of fibrinogen to strain ISP479C or PS12 produced no change in
light transmission (Fig. 6), indicating that no clumping had
occurred.
We then compared strains Newman, ISP479C, and PS12 for
their binding to fibrinogen that had been immobilized in plastic
wells. For Newman, 30.0% ⫾ 1.73% of the inoculum was
bound to immobilized fibrinogen after 1 h (Fig. 7). Of interest,
ISP479C bound 28.52% ⫾ 3.52% of the inoculum under the
same conditions, a level comparable to that of Newman binding. However, only 11.22% ⫾ 3.43% of the PS12 inoculum was
bound, i.e., a 59% reduction in binding relative to ISP479C
(P ⬍ 0.0001, n ⫽ 9). For all strains, the levels of binding to
fibrinogen were significantly higher than binding to plastic
wells treated with casein alone (inoculum-bound values were
0.31% ⫾ 0.29% for Newman, 0.33% ⫾ 0.53% for ISP479C,
and 0.38% ⫾ 0.28% for PS12). These results indicate that ClfA
expressed by ISP479C appears to bind immobilized fibrinogen
preferentially. Mutation of clfA, as has occurred in PS12, results in a loss of this binding.
Effects of rClfA treatment on the binding of S. aureus to
human platelets. To further establish the role of ClfA in me-
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diating platelet binding by S. aureus, we examined the effects of
purified rClfA on the adherence of the bacteria to platelet
monolayers. In control studies with strain PS12, pretreatment
of platelet monolayers with 1 g of rClfA per ml reduced
platelet binding from 4.67% ⫾ 0.40% to 3.44% ⫾ 0.38% of the
inoculum (Fig. 8). No further reduction in binding was seen at
higher concentrations of the recombinant protein. In contrast,
platelet binding by strain ISP479C was progressively reduced
by increasing concentrations of rClfA. Moreover, the levels of
inhibition observed were statistically significant at all concentrations tested. At 50 g of rClfA per ml, platelet binding was
reduced from 6.24% ⫾ 0.73% to 3.51% ⫾ 0.77% of the inoculum, representing a relative reduction of 44%. Of note, this
concentration of rClfA reduced platelet binding by ISP479C to
levels that were comparable to those observed with PS12, when
tested under the same conditions. These results demonstrate
that ClfA can specifically block platelet binding by ISP479C,
indicating that it is a platelet adhesin.
Detection of a ClfA receptor on the platelet membrane. To
assess the binding sites on platelets for ClfA, solubilized platelet membrane proteins were incubated with rClfA, followed by
immunoprecipation with anti-His that had been coupled to

FIG. 6. Clumping of S. aureus by soluble human fibrinogen. Arrows
indicate time points when fibrinogen was added to suspensions of
strain Newman, ISP479C, or PS12. The samples were monitored continuously in an aggregometer for turbidity. Clumping was detected as
an increase in light transmission.
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FIG. 7. Binding of S. aureus to immobilized human fibrinogen. The
levels of binding of strains Newman, ISP479C, and PS12 to human
fibrinogen immobilized in tissue culture wells (⫹FGN) were compared. Casein-blocked wells that had not been coated with fibrinogen
(⫺FGN) served as controls for nonspecific binding. Results are expressed as the means ⫾ standard deviations of nine experiments. The
asterisk indicates statistical significance (P ⬍ 0.0001) compared with
the binding of ISP479C.

protein A. As a control for nonspecific binding, parallel experiments were done in which rClfA was omitted. In these control
studies, several platelet membrane proteins in the 30-to-100kDa range were nonspecifically recovered (Fig. 9, lane 1).
However, when platelet membrane proteins were first incubated with rClfA and then treated with anti-His bound to
protein A, an additional membrane protein of approximately
118 kDa was precipitated (Fig. 9, lane 2).
Of the major platelet membrane proteins characterized to
date, GPIIb has a molecular mass (115 to 130 kDa) closest to
118 kDa (4). To assess if GPIIb was the 118-kDa protein recovered by coimmunoprecipitation with rClfA, we probed
the immunoprecipitated material by Western blotting, using a
monoclonal antibody specific for GPIIb. In control studies using solubilized platelet membrane proteins, GPIIb was readily
detected with this monoclonal antibody. However, no GPIIb
was detected in proteins precipitated with rClfA. These results
indicate that the 118-kDa protein is not GPIIb.
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FIG. 8. Inhibition of staphylococcus-platelet binding by rClfA.
Strains ISP479C and PS12 were added to immobilized platelet monolayers pretreated with 0 to 50 g of rClfA per ml. Binding is expressed
as a percentage of the inoculum (mean ⫾ standard deviation).
ISP479C binding to platelets was significantly reduced at all rClfA
concentrations tested compared with untreated platelets (0 g/ml)
(ⴱ, P ⫽ 0.05; ⴱⴱ, P ⫽ 0.02; ⴱⴱⴱ, P ⬍ 0.0001) (n ⫽ 6). Note that at 50
g/ml of rClfA, binding of ISP479C is reduced to that of PS12.

In addition to binding fibrinogen, our studies indicate that
ClfA can also contribute to platelet binding by S. aureus. Our
sequencing data have shown that the low platelet binding phenotype of strain PS12 is linked to disruption of clfA by transposon insertion within the SD repeat region of the gene. This

DISCUSSION
ClfA has been characterized as a major fibrinogen binding
protein of S. aureus (21). The protein itself has a modular
structure that includes the N-terminal A region containing the
fibrinogen binding site, and an EF hand domain mediating
Ca2⫹ binding (20, 22, 25). Immediately adjacent to the A
region is the SD repeat that is thought to extend the receptor
portion of the protein away from the cell wall (12). The protein
also contains an LPXTG domain, which allows ClfA to be
covalently cross-linked to the bacterial peptidoglycan, at its
C-terminal end (21). In strain Newman, ClfA is able to readily
bind both soluble fibrinogen and fibrinogen immobilized onto
surfaces (21).

FIG. 9. Coimmunoprecipitation of rClfA and platelet membrane
proteins. Biotinylated platelet membranes were solubilized and immunoprecipitated, using an anti-His monoclonal antibody, in the absence
(lane 1) or presence (lane 2) of rClfA. The immunoprecipitates were
separated by SDS-PAGE, transferred to membranes, and visualized by
chemiluminescence using streptavidin conjugated with horseradish
peroxidase. In addition to several proteins that were precipitated nonspecifically, note the additional 118-kDa protein coprecipitated by
rClfA (arrow).
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mutation results in the production of a truncated form of ClfA,
which appears to have lost its cell wall-anchoring domain. As a
consequence, little ClfA remains associated with the bacterial
surface. Disruption of clfA by transposon insertion had no
effect on the transcription of the ORF immediately downstream from the insertion site, indicating that the reduction in
platelet binding associated with this mutation was not due to
polar effects.
Further evidence that ClfA mediates platelet binding by
S. aureus was seen in our studies in which rClfA was assessed
for its ability to inhibit this interaction. In these experiments,
addition of rClfA significantly reduced platelet binding by
strain ISP479C at all concentrations tested. This inhibition was
proportional to the amount of rClfA added to the reaction
mixture, with 50 g of the recombinant protein per ml reducing ISP479C binding by 44%. Of note, the level of platelet
binding by ISP479C observed at this concentration of rClfa was
comparable to that seen with PS12 tested under identical conditions. These results indicate that the quantitative difference
in platelet binding between these two strains can be attributed
to differences in ClfA surface expression. The small reduction
of PS12 binding produced by rClfA may be explained by our
finding that this strain is not totally devoid of cell wall-associated ClfA (Fig. 4). It is possible, therefore, that PS12 continues
to have low-level, ClfA-mediated platelet binding, which was
blocked by the recombinant protein.
These results, in conjunction with our immunoprecipitation
data, indicate that ClfA can mediate the direct binding of
S. aureus to human platelets. Thus, it appears that ClfA is a
multifunctional protein, a property that has recently been
described for a number of bacterial adhesins. For example, the
S. aureus fibronectin binding protein FnbpA has been shown to
also interact with fibrinogen (32). This binding occurs through
a domain resembling the A region of ClfA that is distinct from
the fibronectin binding region of the adhesin. In addition,
protein A has been shown to bind IgG, the gC1qR protein on
platelet membranes, and von Willebrand’s factor (13, 24). The
binding sites within protein A that mediate these interactions
have yet to be defined. Other examples of multifunctional
proteins can be found in the viridans group streptococci, including CshA, SspA, and SspB from Streptococcus gordonii,
and FimA from Streptococcus parasanguis (5, 9, 23). Therefore,
it appears that numerous bacterial adhesins possess multiple
and at times overlapping functions. The impact of multifunctional surface components on virulence is not known. However, it is conceivable that such multipurpose adhesins may
enhance microbial survival under different conditions in vivo.
It was surprising to find that we had isolated a mutant with
a disruption of the clfA gene, since previous characterization of
PS12 indicated that strains PS12 and ISP479C bound comparable amounts of soluble, radiolabeled fibrinogen (29). In our
current study, when we measured binding of soluble fibrinogen
by a turbidimetric assay, both the parental and mutant strains
exhibited minimal clumping in response to fibrinogen. This
suggests that ClfA, at least when expressed by ISP479C, has
minimal binding to soluble fibrinogen. Since S. aureus is known
to produce other fibrinogen binding proteins (32) it is possible
that fibrinogen binding observed in our previous studies was
mediated by these other surface components.
In contrast to our findings with soluble fibrinogen, strains
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ISP479C and PS12 did differ significantly in their binding to
immobilized fibrinogen. Compared with the parental strain,
PS12 had markedly reduced binding to immobilized fibrinogen. It appears, therefore that ClfA expressed by ISP479C
binds immobilized fibrinogen preferentially. The selective recognition of soluble versus immobilized forms of a receptor has
been described for other organisms. For example, the phasedependent binding of S. gordonii antigen I/II to its ligands is
thought to correctly target the organism for colonization (17).
Although a mechanism has not been described for this selective binding by antigen I/II, sequence data indicates how this
differential recognition may occur in ClfA. The fibrinogen
binding A region of clumping factor has been identified and
includes at minimum amino acids 221 to 550 (20). The clfA
gene in ISP479C has a single base pair change (C3T) in this
region, resulting in the replacement of an alanine for a valine
at position 228. In fact, this single alteration is the only difference between the clfA genes in strains Newman and ISP479C.
Although this change does not completely abrogate binding, it
may affect the ability of the protein to interact with fibrinogen
under different conditions.
As for the binding site on platelets for ClfA, our coimmunoprecipitation studies indicate that clumping factor binds to
human platelets directly via a 118-kDa membrane protein. The
identity of this protein is uncertain. Although fibrinogen can be
found on the surface of activated platelets (14), none of its
subunits has a molecular mass similar to that of the membrane
protein identified in our studies (6). Of the characterized platelet membrane proteins, including GPIa, GPIb␣, GPIIa, GPIIb␣,
and GPIIIa, the only receptor with a molecular mass close to
118 kDa is the GPIIb␣ subunit of the integrin ␣IIb␤3 (4).
However, our Western blotting studies using a monoclonal
antibody specific for GPIIb failed to detect the protein in the
ClfA coimmunoprecipitates, indicating that GPIIb is not the
ClfA receptor. It is possible that the ClfA receptor is a known
platelet membrane protein that had atypical electrophoretic
mobility due to the experimental conditions used in our studies. If so, then these studies reveal a previously uncharacterized
function for that protein. It is also possible that this 118-kDa
receptor is a previously unrecognized platelet membrane component. Studies to further characterize this ClfA binding protein are now in progress.
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